GlassScriptPhysician profile
Wendy J Gu
NPI 1740579994
$11,020.29
in general payments reported to CMS, 2019-2025
32 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $1,609 · 2021: $2,316 · 2022: $1,314 · 2023: $1,677 · 2024: $1,731 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,055.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,686.02 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $1,646.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,452.82 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,109.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $839.89 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $788.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $545.70 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $331.28 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $328.62 | 2020-2021 | |
| Boston Scientific Corporation | $280.66 | 2019-2020 | |
| Abbvie INC. | $266.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $265.02 | 2019-2025 | |
| Esperion Therapeutics, INC. | $228.57 | 2020-2025 | Nexletol |
| Pfizer INC. | $219.67 | 2020-2025 | |
| Radius Health, INC. | $192.65 | 2023-2025 | Tymlos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $187.02 | 2023-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $95.86 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $77.43 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.46 | 2022-2023 | |
| Almatica Pharma LLC | $47.60 | 2021-2022 | |
| Gilead Sciences, INC. | $45.46 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $42.43 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $38.32 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.97 | 2021 | |
| Sanofi Pasteur INC. | $21.31 | 2020 | |
| Hologic Sales and Service, LLC | $21.17 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.27 | 2025 | Zoryve |
| Allergan, INC. | $18.87 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.28 | 2021 | |
| Redhill Biopharma INC. | $14.85 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.